Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclic nucleotide-gated cation channel alpha 3 (CNGA3)
- Target
- CNGA3
- Molecular classification
- Ion channel, Cyclic nucleotide-gated channel
01
Overview
Cyclic nucleotide-gated cation channel alpha 3 (CNGA3) is the alpha subunit of cone photoreceptor CNG channels, essential for color vision and daylight vision. It forms heterotetrameric channels with CNGB3, allowing cation influx into cone cells in the dark. Light-induced closure of these channels alters the cell's electrical charge, generating a visual signal. Mutations in CNGA3 are associated with achromatopsia and other forms of color blindness.
- Other names
- ACHM2CCNC1CCNCaCCNCalphaCNCG3CNG3
02
Mechanism of action
Not applicable - CNGA3 is a channel, not a typical drug target. Therapeutic strategies involve gene therapy or other approaches to restore function.
03
Biological functions
Sensory signal transductionPhototransductionCation transport
04
Disease associations
AchromatopsiaColor blindnessRod monochromacy
05
Safety considerations
Potential for off-target effects in gene therapyChallenges in delivering gene therapy specifically to cone photoreceptorsRisk of immune response to gene therapy vectors
Beyond the preview
Go deeper on Cyclic nucleotide-gated cation channel alpha 3 (CNGA3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyclic nucleotide-gated cation channel alpha 3 (CNGA3).